With Two Companies Dictating Everything, IHE Is Riskier Than Most Investors Realize

1 hour ago 1

John Seetoo

Tue, March 24, 2026 astatine 9:07 AM CDT 6 min read

iShares U.S. Pharmaceuticals ETF (IHE) has 46.8% of its $1.1B portfolio concentrated successful Johnson & Johnson (JNJ), up 14% year-to-date connected beardown DARZALEX income of $3.90B, and Eli Lilly (LLY), down 15% year-to-date contempt Mounjaro hitting $7.41B successful Q4 2025 revenue. The money itself is level year-to-date, down 0.5%, reflecting opposing show betwixt its 2 ascendant holdings facing pricing unit and manufacturing constraints.
The Trump administration’s assertive cause pricing betterment done projected CMS rules similar GLOBE and GUARD, combined with HHS Secretary Robert F. Kennedy Jr.’s regulatory scrutiny of the GLP-1 category, is creating structural headwinds that could materially compress revenues crossed the full ETF successful 2026.
Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin discontinue earlier than expected.

Half of each dollar invested successful iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) rides connected conscionable 2 companies pulling successful other directions successful 2026. With a 0.38% disbursal ratio, astir $1.1 cardinal successful nett assets, and a 20-year way grounds dating to May 2006, it offers income-oriented and assemblage investors a focused conveyance for pharmaceutical exposure. Focused vulnerability means the fund's show depends heavy connected a tiny fig of companies navigating superior headwinds.

Multiple amber medicine medicine bottles with achromatic caps basal connected a reflective achromatic aboveground against a acheronian background, with 2 achromatic pills disposable successful the foreground.

Multiple medicine medicine bottles and escaped pills correspond the pharmaceutical industry.

The ETF holds 50 positions, but the apical 2 predominate successful a mode that makes the remainder astir incidental. Johnson & Johnson (NYSE:JNJ) carries a 25.4% weight, and Eli Lilly and Company (NYSE:LLY) sits astatine 21.4%. Together they relationship for astir 46.8% of the full fund. The adjacent six largest holdings each correspond betwixt 4% and 5% of the portfolio. For astir fractional the superior invested, the fund's show is mostly determined by 2 companies.

Have You work The New Report Shaking Up Retirement Plans? Americans are answering 3 questions and galore are realizing they tin retire earlier than expected.

The 2 giants are pulling successful other directions successful 2026, and neither is immune to the regulatory situation bearing down connected the industry.

Johnson & Johnson has held up good comparative to the broader fund. Shares are up astir 14% year-to-date, driven by beardown pharmaceutical growth. DARZALEX generated $3.90 cardinal successful the astir caller quarter, up 26.6% year-over-year, and TREMFYA posted $1.59 billion, up 67.6%. But JNJ faces existent headwinds: STELARA biosimilar erosion chopped that drug's gross by 47.7% successful Q4 2025, and the institution is navigating $854 cardinal successful litigation charges successful the aforesaid quarter. A planned separation of its Orthopaedics conception adds further complexity.

Read Entire Article